These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37690669)

  • 1. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
    Alpizar SA; Accini J; Anderson DC; Eysa B; Medina-Piñón I; Ohmagari N; Ostrovskyy MM; Aggrey-Amable A; Beck K; Byrne D; Grayson S; Hwang PMT; Lonchar JD; Strizki J; Xu Y; Paschke A; De Anda CS; Sears PS;
    J Infect; 2023 Nov; 87(5):392-402. PubMed ID: 37690669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
    Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
    Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
    Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C
    Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
    Johnson MG; Puenpatom A; Moncada PA; Burgess L; Duke ER; Ohmagari N; Wolf T; Bassetti M; Bhagani S; Ghosn J; Zhang Y; Wan H; Williams-Diaz A; Brown ML; Paschke A; De Anda C
    Ann Intern Med; 2022 Aug; 175(8):1126-1134. PubMed ID: 35667065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.
    Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.